23 hours ago The biobank comprises three cryotanks, equipped with cooled protective hoods, and a transfer station from which the sample containers are transported via a rail system. There is enough space for approximately 60,000 samples. Credit: Fraunhofer IBMT

For the development of new drugs it is crucial to work with stem cells, as these allow scientists to study the effects of new active pharmaceutical ingredients. But it has always been difficult to derive enough stem cells of the right quality and in the right timeframe. A central biobank is about to remedy the situation.

Human stem cells allow scientists to assess how patients are likely to respond to new drugs and to examine how illnesses come about. For a few years now, it has been possible to take tissue samples from adults and use reverse programming to artificially produce stem cells, which have the potential to create any kind of cell found in the human body. Before this discovery, pharmaceutical researchers had to use adult stem cells or primary cells, which have a more limited potential. Another option is to use stem cells derived from human embryos, but quite apart from the ethical considerations these cells are available only in limited diversity. The new technique makes it possible for instance to reprogram adult skin or blood cells so that they behave in a similar way to embryonic stem cells and can become any type of cell. "These are known as induced pluripotent stem cells, or iPS cells for short," says Dr. Julia Neubauer from the Fraunhofer Institute for Biomedical Engineering IBMT in St. Ingbert, Germany. Although an increasing number of local biobanks have emerged in recent years, none of them fulfills the requirements of the pharmaceutical industry and research institutions. What is needed is a supply of 'ready-to-use' stem cells, which means large numbers of consistently characterized, systematically catalogued cells of suitable quality.

At the beginning of 2014, the IBMT teamed up with 26 industry and research partners to launch a project aimed at establishing a central biobank the European Bank for induced pluripotent Stem Cells (EBiSC) to generate iPS cells from patients with specific diseases or genetic mutations (http://ebisc.org/). Six months into the project and the first cells are available for use in the development of new drugs. By its three-year mark, it is hoped the project will be in a position to offer over 1000 defined and characterized cell lines comprising a hundred million cells. Such quantities are needed because a single drug screening involves testing several million cells. The main biobank facility is being built in the English city of Cambridge and an identical "mirror site" will be set up at the IBMT's Sulzbach location in Germany.

Gently freezing cells

The IBMT was brought on board for EBiSC by virtue of the comprehensive expertise it gained through participation in the EU's "Hyperlab" and "CRYSTAL" projects. For EBiSC, IBMT scientists are responsible for freezing the cells and for automating cell cultivation and the biobank itself. For an efficient long-term storage of functional stem cells, they have to be cooled down to temperatures of below 130 degrees Celsius in a controlled way. The scientists have to prepare the cells so they can survive the cold shock of nitrogen gas. The IBMT has, for instance, developed technologies that allow cells to be frozen in an extremely gentle way. "Cells don't like being removed from the surface they are grown on, but that's what people used to do in order to freeze them. Our method allows the cells to stay adherent," explains Neubauer.

Just as with foodstuffs, stem cells depend on an unbroken cold chain to preserve their functionality and viability. The scientists store the cells in special containers or cryotanks each measuring one by two meters. To remove a particular sample, the scientists have to open the cryotank. The problem is that this exposes all the other samples to warmer ambient air, causing them to begin to thaw out. "It's just like when you go to your refrigerator at home it's not a good idea to leave the door open too long," says Neubauer. She and her colleagues at the IBMT and industry partner Askion GmbH have together developed a stem cell biobank complete with protective hoods that protect the other samples whenever the cryotank is opened. In addition to maintaining the temperature, the hoods help keep another key shelf-life criterion, humidity, at a constant level.

Flawless freezing is important, but it is just as important to automate the whole process. "That not only guarantees consistency, it's what makes it possible to provide large quantities of cells of the required quality in the first place," says Neubauer. And the scientists' cooling process already boasts a finished technology. In their automated biobank, each cell sample is labelled with barcodes to allow them to be tracked. The samples travel along a conveyor belt to the individual cyrotanks, and a computer monitors the entire freezing and storage process.

Now the scientists are working on automating cell cultivation or the multiplying of the cells. There are essentially two possible approaches. One is to use robots that translate each preparation step into a mechanical one. The other is to use stirred bioreactors that provide free-moving cells with the ideal supply of nutrients and oxygen. Both technologies feature in the IBMT's portfolio. "By the time the project is completed, we'll know which is the better method for what we're trying to do," says Neubauer.

Explore further: Animal-free reprogramming of adult cells improves safety

Continue reading here:
Central biobank for drug research

Cell Therapy for Osteoarthritis
This video is about my PhD investigating the role of microRNAs during chondrogensis of human embryonic stem cells. This research is sponsored by the BBSRC DTP.

By: Rosie Griffiths

Go here to read the rest:
Cell Therapy for Osteoarthritis - Video

ReNeuron Group Quote more

Price: 3.51

Chg: -0.29

Chg %: -7.63%

Date: 11:45

Stem cell therapy group Reneuron said it remains on track with the first patients having been dosed in two its clinical trials.

The phase II trial for the ReN001 cell therapy candidate for stroke disability and the phase I trail for ReN009 cell therapy candidate for critical limb ischaemia have both begun.

The ReN001 trial is on course to have generated six month follow-up data by the end of 2015, while ReN009 study should give results in the first half of next year.

Chief executive officer (CEO) Michael Hunt said that Reneuron's core therapeutic programmes remain on track towards "further important clinical milestones" over the next 18 months.

"In particular, the commencement of dosing of patients in two new clinical trials, in stroke and limb ischaemia, marks another significant step in Reneuron's evolution into a fully-fledged clinical development business and a leading player in the increasingly exciting field of cell therapy and regenerative medicine," Hunt said.

Read more:
Reneuron on track for clinical milestones as studies get underway

Scientific publications from PubMed.gov

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Regen Med. 2013 May;8(3):271-81 Authors: Ning G, Tang L, Wu Q, Li Y, Li Y, Zhang C, Feng S

Abstract AIM: We aim to explore the repair mechanism after the transplantation of CD34(+) human umbilical cord blood cells (HUCBCs) in traumatic spinal cord injury (SCI) in rats.

MATERIALS & METHODS: Wistar rats with SCI were randomly divided into three groups: DMEM injection (group A); CD34(+) HUCBC transplantation on the first day after injury (group B); and CD34(+) HUCBC transplantation on the sixth day after injury (group C). The Basso, Beattie and Bresnahan scores were used to evaluate motor behavior. At the injured site, the infarct size, blood vessel density, and survival and neural differentiation of transplanted cells were analyzed.

RESULTS: It was found that the Basso, Beattie and Bresnahan score in group B was significantly higher than other groups (p < 0.05), and the infarct size and blood vessel density at the injured site were significantly different (p < 0.01). However, the transplanted cells survived at least 3 weeks at the injured site, but did not differentiate into neural cells.

CONCLUSION: These results suggested transplantation of CD34(+) HUCBCs during the acute phase could promote the functional recovery better than during the subacute phase after SCI by raising blood vessel density, suggesting the possible clinical application for the treatment of spinal injury.

PMID: 23627822 [PubMed - indexed for MEDLINE]

Cytotherapy. 2013 Feb;15(2):185-91 Authors: Liu J, Han D, Wang Z, Xue M, Zhu L, Yan H, Zheng X, Guo Z, Wang H

Abstract BACKGROUND AIMS: The purpose of this study was to observe the clinical effect and safety of umbilical cord mesenchymal stem cells (UC-MSCs) in treating spinal cord injury (SCI) by intrathecal injection.

See the original post:
Spinal cord injury and stem cell publications

Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-much-does-stem-cell-therapy-cost/ Find out about how much stem cell therapy will cost you...

By: Thanyapura Health Centre

More:
Stem Cell Activation Phuket, Thailand: How much does stem cell therapy cost - Video

Kansas RMC Stem Cell Therapy in the US
In the past, stem cell treatment was only available in Europe. Now, in the US, we are able to provide this potentially life changing treatment to people like you at a very reasonable price....

By: Digital Concierge

See the article here:
Kansas RMC Stem Cell Therapy in the US - Video

PUBLIC RELEASE DATE:

29-Aug-2014

Contact: Kris Kitto kris@morethanpr.com 303-320-7790 The Bawmann Group

AURORA, Colo. (Sept. 2, 2014) A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications that extend beyond cancer, including treatments for inborn immunodeficiency and metabolic conditions and autoimmune diseases.

In an article published Aug. 29 in PLOS ONE, researchers from the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and Taiga Biotechnologies, Inc. said they have uncovered the keys to the molecular code that appear to regulate the ability of blood stem cells to reproduce and retain their stem-like characteristics.

The team developed protein products that can be directly administered to blood stem cells to encourage them to multiply without permanent genetic modifications.

"Use of stem cells to treat cancer patients who face bone marrow transplants has been a common practice for four decades," said Yosef Refaeli, Ph.D., an associate dermatology professor and one of the study's lead scientists. "The biggest challenge, however, has been finding adequate supplies of stem cells that help patients fight infection after the procedure."

Gates Stem Cell Center Director Dennis Roop, Ph.D., recognized the magnitude of the team's work.

"Researchers have long attempted to increase the number of blood stem cells in a lab," Roop said. "Most of those approaches have been limited by the nature of the resulting cells or the inadequate number of cells produced."

The technology described in the PLOS ONE article has worked with blood stem cells obtained from cord blood, adult bone marrow or peripheral blood from adults.

Originally posted here:
CU scientists' discovery could lead to new cancer treatment

A new research has revealed that three major pigment cell types i.e. black cells, reflective silvery cells, and yellow cells helped in forming the stripes on zebrafish.

The research conducted by Max Planck Institute for Developmental Biology in Tubingen showed that the yellow cells undergo dramatic changes in cell shape to tint the stripe pattern of zebrafish.

First author Prateek Mahalwar said that they were surprised to observe such cell behaviours, which were totally unexpected color pattern formation.

The study revealed that the three cell types reached the skin by completely different routes. A pluripotent cell population situated at the dorsal side of the embryo gave rise to larval yellow cells, which covered the skin of the embryo and began to multiply at the onset of metamorphosis when the fish was about two to three weeks old.

However, the black and silvery cells came from a small set of stem cells, which is associated with nerve nodes located close to the spinal cord in each segment.

Brigitte Walderich, a co-author of the Science paper, explained that they were surprised to discover that the small clusters of fluorescently labelled cells in the embryo, which could be followed during larval and juvenile stages to unravel growth and behaviour of the yellow cells, divided and multiplied as differentiated cells to cover the skin of the fish before the silvery and black cells arrive to form the stripes.

The study is published in journal Science.

(Posted on 29-08-2014)

Information on States of India:

Andaman Nicobar | Andhra Pradesh | Assam | Bihar | Chandigarh | Chhattisgarh | Dadar Nagar Haveli | Daman Diu | Delhi | Goa | Gujarat | Haryana | Himachal Pradesh | Jammu Kashmir | Jharkhand | Karnataka | Kerala | Lakshadweep | Madhya Pradesh | Maharashtra | Manipur | Meghalaya | Mizoram | Nagaland | Orissa | Pondicherry | Punjab | Rajasthan | Sikkim | Tamil Nadu | Tripura | Uttar Pradesh | Uttaranchal | West Bengal

View post:
How zebrafish forms its stripes revealed

The zebrafish, a small fresh water fish, owes its name to a striking pattern of blue stripes alternating with golden stripes. Three major pigment cell types, black cells, reflective silvery cells, and yellow cells emerge during growth in the skin of the tiny juvenile fish and arrange as a multilayered mosaic to compose the characteristic colour pattern. While it was known that all three cell types have to interact to form proper stripes, the embryonic origin of the pigment cells that develop the stripes of the adult fish has remained a mystery up to now. Scientists of the Max Planck Institute for Developmental Biology in Tbingen have now discovered how these cells arise and behave to form the 'zebra' pattern. Their work may help to understand the development and evolution of the great diversity of striking patterns in the animal world.

Beauty in the living world amazes poets, philosophers and scientists alike. Nobel prize laureate Christiane Nsslein-Volhard, Director of the Department for Genetics at the Max Planck Institute for Developmental Biology, has long been fascinated by the biology behind the colour patterns displayed by animals. Her group uses zebrafish as a model organism to study the genetic basis of animal development.

New research by Nsslein-Volhard's laboratory published in Science shows that the yellow cells undergo dramatic changes in cell shape to tint the stripe pattern of zebrafish. "We were surprised to observe such cell behaviours, as these were totally unexpected from what we knew about colour pattern formation," says Prateek Mahalwar, first author of the study. The study builds on a previous work from the laboratory, which was published in June this year in Nature Cell Biology (NCB), tracing the cell behaviour of silvery and black cells. Both studies describe diligent experiments to uncover the cellular events during stripe pattern formation. Individual juvenile fish carrying fluorescently labelled pigment cell precursors were imaged every day for up to three weeks to chart out the cellular behaviours. This enabled the scientists to trace the multiplication, migration and spreading of individual cells and their progeny over the entire patterning process of stripe formation in the living and growing animal. "We had to develop a very gentle procedure to be able to observe individual fish repeatedly over long periods of time. So we used a state of the art microscope which allowed us to reduce the adverse effects of fluorescence illumination to a minimum," says Ajeet Singh, first author of the earlier NCB study.

Surprisingly, the analysis revealed that the three cell types reach the skin by completely different routes: A pluripotent cell population situated at the dorsal side of the embryo gives rise to larval yellow cells, which cover the skin of the embryo. These cells begin to multiply at the onset of metamorphosis when the fish is about two to three weeks old. However, the black and silvery cells come from a small set of stem cells associated with nerve nodes located close to the spinal cord in each segment. The black cells reach the skin migrating along the segmental nerves to appear in the stripe region, whereas the silvery cells pass through the longitudinal cleft that separates the musculature and then multiply and spread in the skin.

Brigitte Walderich, a co-author of the Science paper, who performed cell transplantations to trace the origin of yellow cells, explains: "My attempt was to create small clusters of fluorescently labelled cells in the embryo which could be followed during larval and juvenile stages to unravel growth and behaviour of the yellow cells. We were surprised to discover that they divide and multiply as differentiated cells to cover the skin of the fish before the silvery and black cells arrive to form the stripes."

A striking observation is that both the silvery and yellow cells are able to switch cell shape and colour, depending on their location. The yellow cells compact to closely cover the dense silvery cells forming the light stripe, colouring it golden, and acquire a loose stellate shape over the black cells of the stripes. The silvery cells thinly spread over the stripe region, giving it a blue tint. They switch shape again at a distance into the dense form to aggregate, forming a new light stripe. These cell behaviours create a series of alternating light and dark stripes. The precise superposition of the dense form of silvery and yellow cells in the light stripe, and the loose silvery and yellow cells superimposed over the black cells in the stripe cause the striking contrast between the golden and blue coloration of the pattern.

The authors speculate that variations on these cell behaviours could be at play in generating the great diversity of colour patterns in fish. "These findings inform our way of thinking about colour pattern formation in other fish, but also in animals which are not accessible to direct observation during development such as peacocks, tigers and zebras," says Nsslein-Volhard -- wondering how her cats got their stripes.

Story Source:

The above story is based on materials provided by Max-Planck-Gesellschaft. Note: Materials may be edited for content and length.

See original here:
How the zebrafish gets its stripes: Uncovering how beautiful color patterns can develop in animals

Boston, MA (PRWEB) August 29, 2014

A major challenge before new biotechnology start-up companies, especially ones in the biotech start-up dense realm of Boston-Cambridge, is gaining visibility that can lead to important strategic alliances and able investors. James Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC), has made increasing the local and national visibility of his company an important priority since he started the company in September 2013.

In addition to a social media marketing campaign launched earlier in July of this year, Director Sherley has targeted research and development conferences both nationally and internationally to increase industry awareness of ASCTCs unique portfolio of intellectual property available for licensing and its current commercial development targets. The company is focused on producing two products to address two important needs in drug development and regenerative medicine, respectively, that it is uniquely positioned to address.

ASCTCs most advanced product is an assay that can detect, very early in the drug development pipeline, drug candidates that will ultimately fail because of their toxicity to tissue stem cells. ASCTC developed the new technology in partnership with AlphaSTAR, Corporation, located in Long Beach, California. Currently, such lurking drugs are not detected until after expensive animal testing, more expensive clinical trials, or worse, after marketing. Director Sherley refers to the second product as, A future of pounds and pounds of normal adult tissue stem cells. The company holds a patented technology for mass production of human tissue stem cells. The initial production target is human liver stem cells that can be used to make mature human liver cells for use in drug development and to support liver transplant patients. The company also holds patents for production of pancreatic stem cells and hair follicle stem cells.

The sponsor the 2014 Stem Cells & Regenerative Medicine Conference, in Boston, September 15-16, Terrapinn, Inc., invited ASCTC to attend as a VIP guest. Although ASCTC will not make a formal presentation at this conference, Director Sherley will participate in a roundtable discussion on the topic, Articulating value for up-and-coming regenerative medicine, stem cell and cell-based therapies.

Later in September (22-24), Director Sherley will present one of the selected Next Generation Presentations for new companies at BioPharm America 2014, also taking place in Boston. In addition to the public presentation, ASCTC will also participate in confidential partnering meetings with potential investors and strategic alliance partners arranged by conference organizers.

In October, Director Sherley will present to a primarily academic research audience a more detailed accounting of ASCTCs computer simulation technology for quantifying tissue stem cells in culture. This technology is the basis for the companys new assay for tissue stem cell toxicity. Director Sherley is particularly interested in the response from several experts in tissue stem cell growth dynamics who are invited speakers. The symposium, which will take place at Rhode Island Hospital, a medical affiliate of Brown University in Providence, has the goal of presenting emerging disruptive research in the area of Novel Stem Cells and Vesicles. Director Sherley is a member of the symposium organizing committee. ************************************************************************************************************* The Adult Stem Cell Technology Center, LLC (ASCTC) is a Massachusetts life sciences company established in September 2013. ASCTC Director and founder, James L. Sherley, M.D., Ph.D. is the foremost authority on the unique properties of adult stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing iPSCs. Currently, ASCTC is employing its technological advantages to pursue commercialization of mass-produced therapeutic human liver cells and facile assays that are early warning systems for drug candidates with catastrophic toxicity due to adverse effects against adult tissue stem cells.

Originally posted here:
The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences ...

Stem Cell Activation Phuket, Thailand: How have the stem cell therapy results been so far
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/stem-cell-activation-phuket-thailand-how-have-the-stem-cell-therapy-results-been-so-far/ Client...

By: Thanyapura Health Centre

Go here to read the rest:
Stem Cell Activation Phuket, Thailand: How have the stem cell therapy results been so far - Video

Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-is-your-stem-cell-therapy-different/ Thanyapura Health offers natural stem cell activation,...

By: Thanyapura Health Centre

See the original post:
Stem Cell Activation Phuket, Thailand: How is your stem cell therapy different - Video

Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/how-have-athletes-been-using-stem-cell-therapy/ Using stem cell therapy treats body issue e.g....

By: Thanyapura Health Centre

See the original post:
Stem Cell Activation Phuket, Thailand: How have athletes been using stem cell therapy - Video

Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy
http://www.thanyapurahealth.com/health-services/natural-stem-cell-activationregenerative-therapy/what-type-of-clients-have-you-been-seeing-for-stem-cell-therapy/ Wide range of client who has...

By: Thanyapura Health Centre

Read the original post:
Stem Cell Activation Phuket: What type of clients have you been seeing for stem cell therapy - Video

The medical community has long thought the heart muscle had zero regenerative ability; once it was damaged or otherwise made ineffective, there was no chance of the body making new cells to replace the old ones. That way of thinking is about to change, however, thanks to a new study from Vanderbilt University.

Cardiac stem cells, cells that can create new heart muscle, have been identified inside arteries. The discovery came about as scientists closely examined endothelial cells that line the inner surface of blood vessels. These cells have been known to generate other cells types during mammalian development.

SEE ALSO: Heart attack signs and symptoms in women

People thought that the same heart you had as a young child, you had as an old man or woman as well, said researcher Antonis Hatzopoulos in a press release. Our study suggests that coronary artery disease could lead to heart failure not only by blocking the arteries and causing heart attacks, but also by affecting the way the heart is maintained and regenerated.

What Hatzopoulos and his team suggest is that while the body is healthy and the heart is functioning at a normal level, the cardiac stem cells in the arteries maintain the heart muscle, regenerating cells as needed. When illness like coronary artery disease or a medical emergency like a heart attack occur, these stem cells stop making healthy muscle tissue and start making scar tissue instead. This switch can further complicate heart failure by creating another way arteries become blocked.

It looks like the same endothelial system generates myocytes (muscle cells) during homeostasis and then switches to generate scar tissue after a myocardial infarction. After injury, regeneration turns to fibrosis, said Hatzopoulos. If we can understand the molecular mechanisms that regulate the fate switch that happens after injury, perhaps we can use some sort of chemical or drug to restore regeneration and make muscle instead of scar. We think there is an opportunity here to improve the way we treat people who come into the clinic after myocardial infarction (heart attack).

SEE ALSO: Heart attacks increase health issues in partners, spouses

The key in future research will be to uncover why the cardiac stem cells in the arteries switch from making healthy cells to making scar tissue cells. By learning to control this switch, experts may be able to one day encourage the body to make new heart tissue after a heart attack or to combat age and other disease issues.

See original here:
Cardiac stem cells have been discovered | Voxxi

MANILA The head of the Catholic Bishops' Conference of the Philippines has a reminder to those taking the ice bucket challenge, which supports research efforts of the Amyotrophic Lateral Sclerosis Association (ALSA).

CBCP president Lingayen-Dagupan Archbishop Socrates Villegas said research on ALS involves the use of stem cells.

''ALS is a degenerative disorder and stem-cells apparently hold out the promise of reversing the death and degeneration of brain cells, in particular,'' Villegas said in a statement.

''Stem cells however are most readily harvested from embryos, and it is in this regard that this type of research is ethically problematic."

Citing the ''Instruction on Respect for Human Life in Its Origin and on the Dignity of Procreation,'' Villegas noted that ''human embryos obtained in vitro are human beings and subjects with rights."

ALS is a progressive neurodegenerative disease that attacks nerve cells and pathways in the brain and spinal cord, which eventually leads to paralysis.

Villegas said the ALS Association said in a statement that ''most stem-cell research in ALS is currently focused on iPS (induced pluripotent stem) cells, which are not burdened with ethical issues."

''We are told that iPS cells are 'induced pluripotent stem cells', stem cells created from skin cells. Such cells would indeed be pluripotent, but would not be embryonic cells,'' the CBCP chief said.

''As such, the ethical objection to the use of embryonic cells, whether harvested from embryos, or obtained through in vitro fertilization, would not arise."

The prelate, however, noted that the ALS Association also admitted that ''iPS cells are used in 'most stem-cell research.'''

See the original post:
Catholics warned about ice bucket challenge

CARLSBAD, CA--(Marketwired - August 28, 2014) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw will present a corporate overview of ISCO and its subsidiaries at two upcoming investment conferences.

Rodman and Renshaw 16th Annual Global Investment Conference:

Date:Wednesday, September 10, 2014 Time:11:40 a.m. ET Location:New York Palace Hotel, New York, NY Room:Kennedy I

Conference details:http://www.meetmax.com//sched/event_23003/~public/conference_home.html?event_id=23003

AEGIS CAPITAL Corp. 2014 Healthcare and Technology Conference:Date:Thursday, September 11, 2014 Time:10:45 a.m. PT Location:The Encore at Wynn, Las Vegas, NV

Conference details:http://www.meetmax.com/sched/event_25932/~public/conference_home.html?event_id=25932

Please contact the conference organizers if you have an interest in attending the conference or if you would like to arrange a meeting with International Stem Cell Corporation's management team.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available atwww.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

See more here:
International Stem Cell Corporation to Present at Two Upcoming Investment Conferences

A lot of individuals are regularly making an effort to find the best medications available today because of the presence of a lot of illnesses in the world. New treatments and variations of old ones are hitting the market because of this growing need of people and one of the newest alternatives to medication that experts have come up with is referred to as induced Pluripotent Stem Cell Therapy, also called iPS Cell Therapy or iPSC Therapy. What is Induced Pluripotent Stem Cell therapy?

Regardless if the entire thing is controversial, a ton of experts continue to show interest when it comes to stem cell therapy. Grown inside the laboratory, people are injected with transmuted cells to replace cells that are unhealthy. This is what science fiction is made of, but now almost a reality.

The thing about stem cell therapy is that it garnered and continues to garner a lot of bad publicity in line with moral and ethical concerns. Several years ago, people saw to it that no further research was done on embryonic stem cells but in 2006, studies were conducted by the Japanese but this time, they used mouse cells. More and more people became mindful of and interested in iPSC because of this shift in events.

About 5 years ago, the University of Wisconsin found a way to study iPSC with the help of adult human cells. The thing about iPSC is that people only had problems with the studies when embryonic stem cells were utilized. Because of such an event, efforts have been made to include iPSC processes in Regenerative or Reparative Medicine.

Various illnesses can affect daily living from arthritis to diabetes to burns and iPSC therapies can be a solution to these provided that adequate research is conducted. What you have here can also be utilized for diseases that are genetic in nature like cancer for example. Aside from dealing with spinal cord issues, there is also a chance that iPSC can be used to cure Parkinsons and Alzheimers disease.

There is so much potential in stem cell therapy. Imagine how much good it will do to mankind if healthy cells may scientifically be produced in laboratories and injected into patients. For people with cancer, the cancerous cells can easily be replaced with the ones that are healthy.

What you have here can change the way people look at disease and pain.. Not having to rely on the human body for cell regeneration is something that can lead to thousands of opportunities in health. There is still a need to perfect current research efforts on the matter but this is surely beyond science fiction.

Other than yet merely in experimental stage, the therapies are also very costly. These therapies need more time for experimentation and more years are necessary if you want to lower the costs of the therapies. But scientists remain hopeful.

One of the most popular therapies in line with stem cells these days is bone marrow transplantation. There are various patients that have different cancers related to the bone marrow or blood and this is what this transplantation serves to treat. It is a risky procedure, however, and may have several complications.

In various countries, scientists get support for this type of research. It may take years before people can rely on iPS Cell therapy on a regular basis but even if this is so, all the hard work will surely be well worth it because of the countless benefits that this form of therapy can bring. Pain and disease will be no match for science once this form of therapy is completed.

Originally posted here:
IPS Cell Therapy | Stem Cells Research

Jilly #39;s Miracle post stem cell therapy at Australind Veterinary Hospital
Jilly pain free following stem cell therapy at Australind Veterinary Hospital.

By: AustralindVet

Read more:
Jilly's Miracle post stem cell therapy at Australind Veterinary Hospital - Video

PUBLIC RELEASE DATE:

28-Aug-2014

Contact: Robert Nellis newsbureau@mayo.edu 507-284-5005 Mayo Clinic

ROCHESTER, Minn. A Mayo Clinic researcher and his collaborators have developed an online analytic tool that will speed up and enhance the process of re-engineering cells for biomedical investigation. CellNet is a free-use Internet platform that uses network biology methods to aid stem cell engineering. Details of CellNet and its application to stem cell engineering are described in two back-to-back papers in the journal Cell.

"This free platform has a broad range of uses for all types of cell-based investigations and can potentially offer help to people working on all types of cancer," says Hu Li, Ph.D., investigator in the Mayo Clinic Center for Individualized Medicine and Department of Molecular Pharmacology & Experimental Therapeutics, and co-lead investigator in the two works. "CellNet will indicate how closely an engineered cell resembles the real counterpart and even suggests ways to adjust the engineering."

The network biology platform contains data on a wide range of cells and details on what is known about those cell types. Researchers say the platform can be applied to almost any study and allows users to refine the engineering process. In the long term, it should provide a reliable short cut to the early phases of drug development, individualized cancer therapies, and pharmacogenetics.

CellNet uses 21 cell types and tissues and data from 56 published human and mouse engineering studies as a basis for analyzing and predicting cell fate and corresponding engineering strategies. The platform also offers classification scores to determine differentiation and conversion of induced pluripotent stem cells. It reveals incomplete conversion of engineered microphages and hepatocytes. CellNet can be used for interrogation of cell fate following expression profiling, by classifying input by cell type, quantifying gene regulatory network status, and identifying aberrant regulators affecting the engineering process. All this is valuable in predicting success of engraftment of cancer tumors in mouse avatars for cancer and drug development research. CellNet can be accessed at cellnet.hms.harvard.edu.

###

Co-lead authors with Dr. Li are Patrick Cahan, Ph.D., and Samantha Morris, Ph.D., of Boston Children's Hospital. The senior investigators are George Q. Daley, M.D., Ph.D., Director of the Stem Cell Transplantation Program at Boston Children's and senior investigator on both studies and James Collins, Ph.D., Core Faculty member at the Wyss Institute and the William F. Warren Distinguished Professor at Boston University, co-senior investigator on one of the studies.

Investigators are supported in part by the National Institutes of Health, specifically, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung, and Blood Institute; the Children's Hospital Stem Cell Program; the Howard Hughes Medical Institute; Alex's Lemonade Stand Foundation; the Ellison Medical Foundation; the Doris Duke Medical Foundation; the Mayo Clinic Center for Individualized Medicine and the Mayo Clinic Center for Regenerative Medicine.

View post:
New tool aids stem cell engineering for medical research